Amplify Weight Loss Drug & Treatment ETF (THNR) Performance
THNR total return
Distributions reinvested · as of Oct 23, 2026- YTD
- −2.1% since Dec 31, 2025
- 1 year
- +8.4% total return
- Since first price
- −0.2% since 2024
THNR trailing returns vs SPY, QQQ, AGG
| Period | THNR total return | Price only | S&P 500 (SPY) | Nasdaq-100 (QQQ) | U.S. bonds (AGG) |
|---|---|---|---|---|---|
| 1 month | −5.0% | −5.0% | −1.0% | −5.0% | +0.9% |
| 3 months | −3.8% | −3.8% | +3.2% | +1.9% | −0.4% |
| 6 months | +1.2% | +1.2% | +7.8% | +8.4% | −1.5% |
| YTD | −2.1% | −2.1% | +12.3% | +15.1% | −1.0% |
| 1 year | +8.4% | +6.6% | +14.4% | +15.9% | −1.1% |
| Since inceptionMay 21, 2024 | −0.2% | −2.8% | — | — | — |
Total return from adjusted closes (distributions reinvested, before tax). Periods of 3 years or more are also shown annualized. Price only excludes distributions.
Growth of $10,000: THNR vs SPY
From May 21, 2024: THNR grew to $9,977, SPY to $14,725.
Year-end values with distributions reinvested, no taxes or trading costs. Start: first common trading day of both funds.
THNR returns by calendar year
1 of 1 full years positive. Best 2025 (+13.6%), worst 2025 (+13.6%). 2026 is year to date.
THNR annual returns table
| Year | THNR | Largest drop | SPY | QQQ | AGG |
|---|---|---|---|---|---|
| 2026YTD | −2.1% | −13.9% | +12.3% | +15.1% | −1.0% |
| 2025 | +13.6% | −20.2% | +17.7% | +20.8% | +7.2% |
Largest drop = deepest fall from a high within that calendar year.
Calendar-year return vs largest drop within the year
Most years include a sizable fall at some point even when the year ends higher.
THNR largest drawdowns
Now 11.5% below the high| Peak | Decline | Bottom | Recovered | Fall | Underwater |
|---|---|---|---|---|---|
| Aug 30, 2024 | −32.5% | Apr 8, 2025 | Aug 19, 2026 | 7 months | 2.0 years |
| Aug 25, 2026 | −13.9% | Oct 13, 2026 | not yet | 49 days | 59 days so far |
Declines from a closing high (distributions reinvested) of 10% or more. Underwater = time from the peak until the old high was regained.
THNR risk statistics
| Statistic | Since 2024 |
|---|---|
| Annualized return | +0.8% |
| Volatility (annualized) | 15.2% |
| Sharpe ratio | -0.15 |
| Sortino ratio | -0.20 |
| Best month | +11.6% |
| Worst month | −8.3% |
| Best 12 months | +18.3% |
| Worst 12 months | −17.9% |
| Positive months | 54% |
| Beta vs S&P 500 | — |
| Correlation with S&P 500 | — |
From monthly total returns. Sharpe and Sortino use 1–3 month T-bills (BIL) as the risk-free rate, so they need history from 2007 on.
THNR rolling returns
| Holding period | Periods | Worst | Median | Best | Positive |
|---|---|---|---|---|---|
| 1-year | 18 | −17.9% | +10.8% | +18.3% | 67% |
Every holding period starting at a month-end since 2024. Returns for 3 years and longer are annualized.
THNR performance overview
Amplify Weight Loss Drug & Treatment ETF (THNR) returned +8.4% over the past year, with distributions reinvested. Since its first recorded price on May 21, 2024 it has returned −0.2%. Over the same year S&P 500 (SPY) returned +14.4%.
The deepest decline was −32.5%, from Aug 30, 2024 to Apr 8, 2025, and it took 1.4 years to get back to the old high. Volatility has been 15.2% a year.
Related: THNR chart, THNR holdings, THNR dividends. See the THNR overview for the latest quote and fund facts.
THNR performance FAQ
What is the THNR return over the past year?
THNR returned +8.4% over the 12 months to October 23, 2026, including reinvested distributions. On price alone it rose 6.6%.
How much would $10,000 invested in THNR be worth?
$10,000 invested in THNR at its first recorded close on May 21, 2024 would be worth about $9,977 on October 23, 2026 with distributions reinvested.
What is the biggest drawdown of THNR?
The largest peak-to-trough decline was −32.5% between August 30, 2024 and April 8, 2025. It recovered to the old high on August 19, 2026, 1.4 years after the bottom.
How volatile is THNR?
Over the past history THNR had an annualized volatility of 15.2% and a Sharpe ratio of -0.15 (excess return over 1–3 month T-bills per unit of risk).